WHO's Most Promising Ebola Vaccine to Undergo Human Trials in Singapore
The World Health Organization (WHO) has identified a single-dose vaccine candidate, "rVSV Bundibugyo," as its most promising against the Ebola virus, specifically the Bundibugyo strain. This strain, previously rare, is currently affecting the Democratic Republic of Congo (DRC), where the epidemic has claimed over 1,300 lives since its start. Hilleman Laboratories, a joint venture between U.S. pharmaceutical giant MSD and the U.K. charity Wellcome Trust, announced on Thursday, May 30th, that it will advance the vaccine's development for human clinical trials in Singapore. The vaccine utilizes the same reusable development platform as the approved Ervebo vaccine, which targets the more prevalent Zaire strain of Ebola. MSD, the developer of Ervebo, will provide technical consultation and expertise on the rVSV platform. If initial trials are successful and the vaccine is authorized, Hilleman Laboratories and the Coalition for Epidemic Preparedness Innovations (CEPI), which is funding the development, aim to ensure rapid and affordable access to doses for affected and low-to-middle-income countries. A key advantage anticipated for this new vaccine is its potential to be stored for several months in standard refrigerators, unlike Ervebo which requires ultra-low temperatures, potentially reducing distribution costs and complexity. This development comes as another vaccine for the Bundibugyo virus, using technology similar to AstraZeneca's COVID-19 vaccine, recently began its first human trials with a volunteer receiving a dose.
The development of a promising Ebola vaccine candidate, particularly for the less common Bundibugyo strain, highlights the ongoing global health imperative to address emerging infectious diseases. The collaborative effort involving the WHO, Hilleman Laboratories, MSD, Wellcome Trust, and CEPI demonstrates a structured approach to vaccine development and deployment, leveraging existing platforms and funding mechanisms. The potential for improved storage conditions compared to previous Ebola vaccines signifies a critical advancement in logistical feasibility for widespread distribution, especially in resource-limited settings. This initiative underscores the evolving strategies in pandemic preparedness, aiming to create accessible and stable countermeasures against diverse viral threats, thereby mitigating the systemic risks posed by epidemic outbreaks in vulnerable regions.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.